EyeGene Statistics

Total Valuation

EyeGene has a market cap or net worth of KRW 80.14 billion. The enterprise value is 47.19 billion.

Market Cap	80.14B
Enterprise Value	47.19B

Important Dates

The last earnings date was Thursday, November 14, 2024.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

EyeGene has 27.03 million shares outstanding. The number of shares has increased by 13.65% in one year.

Current Share Class	n/a
Shares Outstanding	27.03M
Shares Change (YoY)	+13.65%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	6.59%
Owned by Institutions (%)	0.10%
Float	19.44M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	25.49
PB Ratio	1.43
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.83
EV / Sales	16.61
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.60

Financial Position

The company has a current ratio of 7.33, with a Debt / Equity ratio of 0.07.

Current Ratio	7.33
Quick Ratio	7.13
Debt / Equity	0.07
Debt / EBITDA	n/a
Debt / FCF	-0.21
Interest Coverage	-30.46

Financial Efficiency

Return on equity (ROE) is -24.45% and return on invested capital (ROIC) is -19.07%.

Return on Equity (ROE)	-24.45%
Return on Assets (ROA)	-16.40%
Return on Capital (ROIC)	-19.07%
Revenue Per Employee	60.44M
Profits Per Employee	-262.45M
Employee Count	47
Asset Turnover	0.04
Inventory Turnover	4.00

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -4.29% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-4.29%
50-Day Moving Average	3,047.30
200-Day Moving Average	3,113.03
Relative Strength Index (RSI)	54.29
Average Volume (20 Days)	43,671

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, EyeGene had revenue of KRW 2.84 billion and -12.34 billion in losses. Loss per share was -505.15.

Revenue	2.84B
Gross Profit	1.71B
Operating Income	-18.02B
Pretax Income	-13.71B
Net Income	-12.34B
EBITDA	-15.51B
EBIT	-18.02B
Loss Per Share	-505.15

Full Income Statement

Balance Sheet

The company has 37.26 billion in cash and 3.79 billion in debt, giving a net cash position of 33.47 billion or 1,238.40 per share.

Cash & Cash Equivalents	37.26B
Total Debt	3.79B
Net Cash	33.47B
Net Cash Per Share	1,238.40
Equity (Book Value)	56.49B
Book Value Per Share	2,070.80
Working Capital	33.62B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -17.24 billion and capital expenditures -931.54 million, giving a free cash flow of -18.17 billion.

Operating Cash Flow	-17.24B
Capital Expenditures	-931.54M
Free Cash Flow	-18.17B
FCF Per Share	-672.37

Full Cash Flow Statement

Margins

Gross Margin	60.20%
Operating Margin	-634.26%
Pretax Margin	-482.62%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-639.76%

Dividends & Yields

EyeGene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-13.65%
Shareholder Yield	-13.65%
Earnings Yield	-17.04%
FCF Yield	-22.68%

Stock Splits

The last stock split was on June 28, 2021. It was a forward split with a ratio of 1.2.

Last Split Date	Jun 28, 2021
Split Type	Forward
Split Ratio	1.2

Scores

EyeGene has an Altman Z-Score of 0.28. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.28
Piotroski F-Score	n/a